<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3519">
  <stage>Registered</stage>
  <submitdate>9/04/2012</submitdate>
  <approvaldate>9/04/2012</approvaldate>
  <nctid>NCT01578655</nctid>
  <trial_identification>
    <studytitle>Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer</studytitle>
    <scientifictitle>A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)</scientifictitle>
    <utrn />
    <trialacronym>AFFINITY</trialacronym>
    <secondaryid>OGX-011-12</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prostate Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - cabazitaxel
Treatment: drugs - prednisone
Treatment: drugs - custirsen sodium

Experimental: Cabazitaxel plus Custirsen - cabazitaxel, prednisone, and custirsen sodium

Active Comparator: Cabazitaxel - cabazitaxel and prednisone


Treatment: drugs: cabazitaxel
Cabazitaxel (25mg/m² IV) is administered on day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles

Treatment: drugs: prednisone
Prednisone (10 mg PO) is administered daily until disease progression, unacceptable toxicity, or completion of 10 cycles

Treatment: drugs: custirsen sodium
Custirsen is administered as 3 loading doses (640 mg IV each) within 9 days, followed by weekly custirsen (640 mg IV) during each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Survival in the intent-to-treat population - To determine whether the survival for patients randomized to the investigational arm (cabazitaxel/prednisone plus custirsen) is consistent with longer survival as compared to patients randomized to the control arm (cabazitaxel/prednisone).</outcome>
      <timepoint>3.4 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Survival in the poor-prognosis patient population - To determine whether the survival for patients randomized to the investigational arm (cabazitaxel/prednisone plus custirsen) and identified as having poor prognosis is consistent with longer survival as compared to patients randomized to the control arm (cabazitaxel/prednisone) and identified as having poor prognosis.</outcome>
      <timepoint>2.7 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival at Day 140 - To compare the arms with respect to the proportion of patients having a milestone Day 140 status of Alive Without Event (within the window of Day 125-155 post-randomization). An event is defined as disease progression or death on or before Day 140.</outcome>
      <timepoint>From randomization to Day 125 to Day 155</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histological or cytological diagnosis of adenocarcinoma of the prostate

          -  Metastatic disease on chest, abdominal, or pelvic CT scan and/or bone scan

          -  Previous first-line treatment for CRPC with a docetaxel-containing regimen

          -  Current progressive disease

          -  Increasing serum PSA level (for patients who progress based only on increasing serum
             PSA level, a minimum starting value of 5.0 ng/mL is required)

          -  Baseline laboratory values as defined

          -  Willing to continue primary androgen suppression with gonadotropin-releasing hormone
             (GnRH) analogues (unless treated with bilateral orchiectomy)

          -  Karnofsky score =70%

          -  At least 21 days have passed since completing radiotherapy

          -  At least 21 days have passed since receiving any investigational agent at the time of
             randomization

          -  At least 21 days have passed since major surgery

          -  Recovered from any docetaxel therapy-related neuropathy to =grade 1 at the time of
             randomization

          -  Recovered from all therapy related toxicity to =grade 2 (except alopecia, anemia, and
             any signs or symptoms of androgen deprivation therapy) at the time of randomization

          -  Able to tolerate a starting dose of 25 mg/m² cabazitaxel

          -  Willing to not add, delete, or change current bisphosphonate or denosumab usage

          -  Able to tolerate oral prednisone at 10 mg per day

          -  Competent to provide written informed consent</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Received any other cytotoxic chemotherapy beyond the first-line docetaxel-containing
             regimen as treatment for prostate cancer

          -  Received prior radioisotope with strontium 89 or samarium 153

          -  Received any cycling, intermittent, or continuous hormonal treatment within 21 days
             prior to randomization with the exception of the continuous GnRH analogues (prior
             treatment with abiraterone or MDV3100 is allowed as long as 21 days have passed since
             last dose)

          -  Participated in a prior Phase 3 clinical study evaluating custirsen regardless of
             study arm assignment

          -  Requiring ongoing treatment during the study with medications known to be either
             strong CYP3A inhibitors or strong CYP3A inducers

          -  History of or current documented brain metastasis or carcinomatous meningitis, treated
             or untreated

          -  Current symptomatic cord compression requiring surgery or radiation therapy

          -  Active second malignancy (except non melanomatous skin or superficial bladder cancer)
             defined in general as requiring anticancer therapy or at high risk of recurrence
             during the study

          -  Uncontrolled medical condition or significant concurrent illness that in the opinion
             of the Investigator would preclude protocol therapy

          -  Known severe hypersensitivity to taxanes or polysorbate 80-containing drugs

          -  Planned concomitant participation in another clinical trial of an experimental agent,
             vaccine, or device</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>630</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,SA,TAS,VIC</recruitmentstate>
    <hospital>The Canberra Hospital - Garran</hospital>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>St George Public Hospital - Kogarah</hospital>
    <hospital>Royal North Shore Hospital - Saint Leonards</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Haematology and Oncology Clinics of Australia - Brisbane</hospital>
    <hospital>The Queen Elizabeth Hospital - Woodville South</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Austin Health - Heidelberg</hospital>
    <hospital>Epworth Healthcare - Richmond</hospital>
    <postcode> - Garran</postcode>
    <postcode> - Camperdown</postcode>
    <postcode> - Kogarah</postcode>
    <postcode> - Saint Leonards</postcode>
    <postcode> - Westmead</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Woodville South</postcode>
    <postcode> - Hobart</postcode>
    <postcode> - Box Hill</postcode>
    <postcode> - Heidelberg</postcode>
    <postcode> - Richmond</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Severomoravsky Kraj</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Hradec Králové</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Liberec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Basse-Normandie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Champagne-Ardenne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Ile de France</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Ile-de-France</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pays de la Loire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Poitou-Charentes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Provence Alpes Cote d'Azur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rhone-Alpes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Bekes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Borsod-Abauj-Zemplen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Csongrad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ural</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Volgograd</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Barnaul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ivanovo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Omsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Stavropol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>England</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Scotland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Achieve Life Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This Phase 3 study has been designed to confirm that adding custirsen to
      cabazitaxel/prednisone treatment can slow tumor progression and enhance survival outcomes
      compared to standard cabazitaxel/prednisone treatment in men with metastatic castrate
      resistant prostate cancer (CRPC). This will be a randomized, open-label, multicenter,
      international trial. Treatment will consist of cabazitaxel/prednisone/custirsen vs.
      cabazitaxel/prednisone. A total of approximately 630 patients will be randomized with equal
      probability to the two arms.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01578655</trialwebsite>
    <publication>Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, Winquist E; Canadian Uro-Oncology Group. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res. 2011 Sep 1;17(17):5765-73. doi: 10.1158/1078-0432.CCR-11-0859. Epub 2011 Jul 25.
Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Sep 20;28(27):4247-54. doi: 10.1200/JCO.2009.26.8771. Epub 2010 Aug 23.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Thomasz Beer, MD</name>
      <address>Oregon Health &amp; Science University, Portland, Oregon</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>